Detalles de la búsqueda
1.
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
N Engl J Med
; 386(14): 1314-1326, 2022 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35196424
2.
Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study.
Viruses
; 15(3)2023 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36992306
3.
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
AIDS
; 37(1): 105-112, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36476455
4.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273491
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416193
Resultados
1 -
5
de 5
1
Próxima >
>>